|Values are valid only on day of printing.|
To better accommodate important updates in the screening guidelines for HPV, an infection present in 20 million people in the United States and resulting in 6.2 million new infections per year, Mayo Medical Laboratories now offers testing for the detection of high-risk HPV (hrHPV), with genotyping for HPV-16 and HPV-18.
A recent study published in the American Journal of Clinical Pathology1 evaluated the role of HPV-16 and -18 genotyping in women with a positive high risk HPV Nucleic Acid Amplification Test (NAAT) result, but negative cytology. The data from this study suggested:
The conclusion that genotyping is important in triaging women with hrHPV has been supported in several studies, including one that concluded “Incorporating screening with HPV and triage of HPV-positive women by a combination of genotyping for HPV-16/18 and cytology provided a good balance between maximizing sensitivity and specificity by limiting the number of colposcopies.”2
A seminal study of 20,810 women with normal cytology in the Kaiser Permanente healthcare system found that women with normal cytology who were HPV-16+ and HPV-18+ had highest risk of developing grade 3 or higher CIN
Both graphs adapted from “cobas® HPV Test: Know the Risk” educational booklet. Used with permission from Roche Molecular Systems, Branchburg, NJ."